A

ADARx Pharmaceuticals, Inc.

ADRXPriced

ADARx Pharmaceuticals, Inc. · Nasdaq Global Market · Research source · 424B4 · 2026-09-28 · Latest filing · 10-Q · 2026-11-12 SEC ↗

Report source
Research source · 424B4 · 2026-09-28
SummaryBASIC RESEARCHReport source · 424B4

ADARx priced its IPO at $17, with AbbVie participation and substantial clinical-stage funding needs.

As of the September 28, 2026 Form 424B4, ADARx proposed 26.25 million primary shares at $17.00 and a concurrent AbbVie private placement.

Ownership and votingAwaiting verified holder data— economic · — voting
Next disclosed checkpointThe filing states expected delivery on or about September 28, 2026; completion and confirmed trading require subsequent verification.424B4 · 2026-09-28
Business and development direction

ADARx Pharmaceuticals, Inc.

Current business
Future development
DECISION DRIVERS

Key risks

Risk 1

The company has not completed any clinical programs and has no products approved for commercial sale.

Risk 2

The company expects significant losses and may require substantial additional funding, causing future dilution.

Risk 3

Third parties conduct preclinical studies, clinical trials and manufacturing, creating execution and timing dependencies.

Next checkThe filing states expected delivery on or about September 28, 2026; completion and confirmed trading require subsequent verification.
Latest filing2026-11-12
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Offering qualitySome sourced inputs are available; a compatible set is needed for this view. Open filing ↗
BOOKRUNNERS / LEAD UNDERWRITERSUnderwriters named in the prospectus
CONFIRMED
#InstitutionUnderwriting allocationRatio · calculatedShares
1J.P. Morgan Securities LLC29.00%7,612,500 shares
2Morgan Stanley & Co. LLC27.00%7,087,500 shares
3TD Securities (USA) LLC20.00%5,250,000 shares
4UBS Securities LLC17.00%4,462,500 shares
5LifeSci Capital LLC7.00%1,837,500 shares

Ratio = institution commitment ÷ complete source-table total (26,250,000 shares) × 100.

Source and calculation

Allocation ratios are calculated from each reported commitment and the complete total in the same source table; they are not ownership or fee percentages.

Underwriting purchase commitments as disclosed; shares; source class retained in the column header; source column: Numberof shares

Numberof shares

SEC table 618 row 10; source 1655643:1659579; SHA256 1a1bb1cd783f9b58a89f9584c1324be43a3d324df22fbb7a213682d29142284f

J.P. Morgan Securities LLC: 7612500 / 26250000 × 100

Morgan Stanley & Co. LLC: 7087500 / 26250000 × 100

TD Securities (USA) LLC: 5250000 / 26250000 × 100

UBS Securities LLC: 4462500 / 26250000 × 100

LifeSci Capital LLC: 1837500 / 26250000 × 100

Source · 424B4 ↗

Underwriting terms

Underwriting terms
MeasureReported valueUnit
Underwriting discount per share$1.19$ / share
Total underwriting discount$31,237,500$
Source and calculation

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Underwriting discount per share

Base prospectus offering; cover per-share and total columns

SEC table 1 row 7; source 2129:5814; SHA256 db14ad19263fb38be3f30841a87c33775e2a82969bc780ebaea5052c079f6555 ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Total underwriting discount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 7; source 2129:5814; SHA256 db14ad19263fb38be3f30841a87c33775e2a82969bc780ebaea5052c079f6555 ↗

IPO CAPITAL QUALITY

Offering price $ / share$17
Gross offering amount $$446,250,000
Shares offered Shares26,250,000
Underwriting discount per share $ / share$1.19
Basis and evidence

424B4 · 2026-09-28

As of the September 28, 2026 Form 424B4, ADARx proposed 26.25 million primary shares at $17.00 and a concurrent AbbVie private placement.

Offering structure

Offering terms
MeasureReported valueUnit
Primary shares · ADARx Pharmaceuticals, Inc.26,250,000Shares
Secondary shares · AbbVie Inc.5,233,264Shares
Shares offered26,250,000Shares
Offering price$17$ / share
Gross offering amount$446,250,000$
Source and calculation

Shares offered by issuer Reported inputs; each row retains its own source basis.

Primary shares · ADARx Pharmaceuticals, Inc.

Shares offered by issuer

Cover and opening disclosure ↗

Concurrent private placement shares; contingent on offering closing Reported inputs; each row retains its own source basis.

Secondary shares · AbbVie Inc.

Concurrent private placement shares; contingent on offering closing

The offering ↗

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

Shares offered

Prospectus offering table; stated base scenario and source conditions

SEC table 56 row 1; source 117658:117991; SHA256 c35d0d99684db04c463859954d3064380d3fbde785bd3213b6ca8f80d5db98d0 ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Gross offering amount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 5; source 2129:5814; SHA256 db14ad19263fb38be3f30841a87c33775e2a82969bc780ebaea5052c079f6555 ↗
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Use of proceedsSource-linked structured inputs are not yet available. Open filing ↗

Dilution and valuation

IPO price$17Final
Basic post-offer≈ 106.8013M
Equity value≈ $1.8156B
Dilution and valuation
CalculationSharesValueReference
Base post-offer valuation≈ 106.8013M≈ $1.8156B
Derived calculationFinalshares · $Basis and evidence 10 ↗
Post-offer shares — base/no option106,801,325—
Reported sourcePost-offer · BasesharesBasis and evidence 8 ↗
Post-offer shares — full option110,738,825—
Reported sourcePost-offer · Full optionsharesBasis and evidence 8 ↗
Capitalization shares — actual9,669,578—
Reported sourceCommon stock; actualsharesBasis and evidence 3 ↗
Capitalization shares — pro forma75,318,061—
Reported sourceCommon stock; pro formasharesBasis and evidence 4 ↗
Capitalization shares — pro forma as adjusted106,801,325—
Reported sourceCommon stock; pro forma as adjustedsharesBasis and evidence 5 ↗
Shares offered26,250,000—
Reported sourcesharesBasis and evidence 6 ↗
Offering price—$17
Reported sourceFinal$/shareBasis and evidence 7 ↗
Gross offering amount—$446,250,000
Reported source$Basis and evidence 7 ↗
Basis and evidence ↗
Basis and evidence 1

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 59 row 1 columns 2; share summary; label column 1; source 120314:120821; SHA256 dcf718b242b5963b495171f3d45495900aeee55ad11f3da8d2fe007029e63590 ↗

Basis and evidence 2

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 59 row 1 columns 2; share summary; label column 1; source 120314:120821; SHA256 dcf718b242b5963b495171f3d45495900aeee55ad11f3da8d2fe007029e63590 ↗

Basis and evidence 3

Capitalization share count; source stage: actual; Common stock, par value $0.0001 per share; 110,000,000 shares authorized, 9,669,578 shares issued and outstanding, actual 999,999,999 shares authorized, 75,318,061 shares issued and outstanding, pro forma; and 999,999,999 shares authorized, 106,801,325 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 318 row 11 columns 1; share summary; label column 1; source 691303:702950; SHA256 6e5feb7f6303738e3136f41f7f97944a312eedee53da2863e43e35fe4f4bbd85 ↗

Basis and evidence 4

Capitalization share count; source stage: pro forma; Common stock, par value $0.0001 per share; 110,000,000 shares authorized, 9,669,578 shares issued and outstanding, actual 999,999,999 shares authorized, 75,318,061 shares issued and outstanding, pro forma; and 999,999,999 shares authorized, 106,801,325 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 318 row 11 columns 1; share summary; label column 1; source 691303:702950; SHA256 6e5feb7f6303738e3136f41f7f97944a312eedee53da2863e43e35fe4f4bbd85 ↗

Basis and evidence 5

Capitalization share count; source stage: pro forma as adjusted; Common stock, par value $0.0001 per share; 110,000,000 shares authorized, 9,669,578 shares issued and outstanding, actual 999,999,999 shares authorized, 75,318,061 shares issued and outstanding, pro forma; and 999,999,999 shares authorized, 106,801,325 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 318 row 11 columns 1; share summary; label column 1; source 691303:702950; SHA256 6e5feb7f6303738e3136f41f7f97944a312eedee53da2863e43e35fe4f4bbd85 ↗

Basis and evidence 6

Prospectus offering table; stated base scenario and source conditions

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

SEC table 56 row 1; source 117658:117991; SHA256 c35d0d99684db04c463859954d3064380d3fbde785bd3213b6ca8f80d5db98d0 ↗

Basis and evidence 7

Base prospectus offering; cover per-share and total columns

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

SEC table 1 row 5; source 2129:5814; SHA256 db14ad19263fb38be3f30841a87c33775e2a82969bc780ebaea5052c079f6555 ↗

Basis and evidence 8

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Offering price: $17

Exact input · Post-offer shares — base/no option: 106,801,325

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — full option: 110,738,825

SEC table 1 row 5; source 2129:5814; SHA256 db14ad19263fb38be3f30841a87c33775e2a82969bc780ebaea5052c079f6555 ↗

SEC table 59 row 1 columns 2; share summary; label column 1; source 120314:120821; SHA256 dcf718b242b5963b495171f3d45495900aeee55ad11f3da8d2fe007029e63590 ↗

SEC valuation primary issuer cover; source 1142:1466; SHA256 56ac0c7c2874ae5b50debc36f1c1a35e69db389fc1b257ff4c14d636b9f0ebd2 ↗

SEC valuation summary conditions; source 116783:117588; SHA256 d3a32d3f2f7cf90fd4ba843d77817a680e7cab4eadf7a361282b4c391e2ea6b8 ↗

SEC valuation summary conditions; source 122694:164777; SHA256 0d266c8a8c82895acda06ee81e544bf9e431a3e1a899530a8e6e0a943ba7870c ↗

Basis and evidence 9

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

SEC table 1 row 5; source 2129:5814; SHA256 db14ad19263fb38be3f30841a87c33775e2a82969bc780ebaea5052c079f6555 ↗

SEC table 59 row 1 columns 2; share summary; label column 1; source 120314:120821; SHA256 dcf718b242b5963b495171f3d45495900aeee55ad11f3da8d2fe007029e63590 ↗

SEC valuation primary issuer cover; source 1142:1466; SHA256 56ac0c7c2874ae5b50debc36f1c1a35e69db389fc1b257ff4c14d636b9f0ebd2 ↗

SEC valuation summary conditions; source 116783:117588; SHA256 d3a32d3f2f7cf90fd4ba843d77817a680e7cab4eadf7a361282b4c391e2ea6b8 ↗

SEC valuation summary conditions; source 122694:164777; SHA256 0d266c8a8c82895acda06ee81e544bf9e431a3e1a899530a8e6e0a943ba7870c ↗

Basis and evidence 10

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — base/no option: 106,801,325

Exact input · Offering price: $17

SEC table 1 row 5; source 2129:5814; SHA256 db14ad19263fb38be3f30841a87c33775e2a82969bc780ebaea5052c079f6555 ↗

SEC table 59 row 1 columns 2; share summary; label column 1; source 120314:120821; SHA256 dcf718b242b5963b495171f3d45495900aeee55ad11f3da8d2fe007029e63590 ↗

SEC valuation primary issuer cover; source 1142:1466; SHA256 56ac0c7c2874ae5b50debc36f1c1a35e69db389fc1b257ff4c14d636b9f0ebd2 ↗

SEC valuation summary conditions; source 116783:117588; SHA256 d3a32d3f2f7cf90fd4ba843d77817a680e7cab4eadf7a361282b4c391e2ea6b8 ↗

SEC valuation summary conditions; source 122694:164777; SHA256 0d266c8a8c82895acda06ee81e544bf9e431a3e1a899530a8e6e0a943ba7870c ↗

Share-count comparison

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Source ↗
SCENARIO · NOT A FORECAST

IPO valuation scenario simulator

Offering completion · $17 × ≈ 106.8013M shares · Final

Implied equity value≈ $1.8156BPrice × post-offer shares
Post-offer shares≈ 106.8013MShare count, not tradable float
Existing-holder ownership reduction0.0%Assumes new shares only; secondary sales do not increase shares.
Source and calculation ↗
Security and offer price

Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.

Base post-offer shares

Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.

Equity value

Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.

Share-count change

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Alternative scenarios

Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.

Sensitivity

The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.

Source and calculation

The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.

$17 × 106,801,325 = $1,815,622,525 [summary-table-59-base-1-price, summary-table-59-base-1-post]

Exact calculation · Derived whole-issuer equity value: $1,815,622,525

Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Ownership across stagesSome sourced inputs are available; a compatible set is needed for this view. Open filing ↗
As of
2026-09-28
!Post-offer shares are based on 75,318,061 shares after preferred conversion, plus the IPO and AbbVie placement. Existing officers, directors and >5% holders are described as holding approximately 54% in aggregate; the supplied evidence does not provide full holder-by-holder voting totals.View source ↗
Relationship filters
Show
ownership / voting rights
share structure
Select for details · ADARx Pharmaceuticals, Inc.
Founder / personFund / entityPublic floatShare classEvery relationship is dated and linked to its supporting SEC filing. Percentages marked * are filing-based estimates.

Holdings and voting rights

Holder groups may overlap; these rows are not an additive ownership partition.

Holdings and voting rights
Holder / measureSharesOwnershipVoting rightsReference
our executive officers, directors and stockholders whoOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: owned; primary source clause; source condition: assuming no purchase of shares in this offering and concurrent private placement by any of this group); source scope: of our outstanding common stock before this offering and concurrent private placement and their respective affiliates will, in the aggregate, hold approximately; not an additive ownership partitionDisclosedEvidence
our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and concurrent private placement and their respective affiliatesOwnership as disclosed—approximately 54%Beneficial—
Source statement; approximately ; source predicate: will, in the aggregate, hold; primary source clause; source condition: assuming no purchase of shares in this offering and concurrent private placement by any of this group); source scope: of our outstanding common stock (based on the number of shares of our outstanding common stock as of August 25, 2026 and assuming no purchase of shares in this offering and concurrent private placeme; not an additive ownership partitionDisclosedEvidence
Entities affiliated with OrbiMedBeneficial shares23,255,789——
Number ofshares ofbeneficiallyownedDisclosedEvidence
Entities affiliated with LAV FundBeneficial shares11,858,655——
Number ofshares ofbeneficiallyownedDisclosedEvidence
Entities affiliated with SR OneBeneficial shares8,336,661——
Number ofshares ofbeneficiallyownedDisclosedEvidence
Zhen Li, Ph.D.Beneficial shares10,748,214——
Number ofshares ofbeneficiallyownedDisclosedEvidence
BCLS Fund III Investments, LPBeneficial shares5,128,970——
Number ofshares ofbeneficiallyownedDisclosedEvidence
A. Robert MacLeod, Ph.D.Beneficial shares491,898——
Number ofshares ofbeneficiallyownedDisclosedEvidence
Chen Yu, M.D., M.B.A.Beneficial shares3,590,279——
Number ofshares ofbeneficiallyownedDisclosedEvidence
Simeon George, M.D., M.B.A.Beneficial shares8,336,661——
Number ofshares ofbeneficiallyownedDisclosedEvidence
Erez Chimovits, M.B.A.Beneficial shares9,230,509——
Number ofshares ofbeneficiallyownedDisclosedEvidence
Carl L. Gordon, Ph.D., CFABeneficial shares23,255,789——
Number ofshares ofbeneficiallyownedDisclosedEvidence
All current executive officers and directors as a group (14 persons)Beneficial shares50,193,162——
Number ofshares ofbeneficiallyownedDisclosedEvidence
Entities affiliated with OrbiMedBeneficial ownership—30.8%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Entities affiliated with OrbiMedBeneficial ownership—21.8%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
Entities affiliated with LAV FundBeneficial ownership—15.7%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Entities affiliated with LAV FundBeneficial ownership—11.1%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
Entities affiliated with SR OneBeneficial ownership—11.1%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Entities affiliated with SR OneBeneficial ownership—7.8%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
Zhen Li, Ph.D.Beneficial ownership—13.4%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Zhen Li, Ph.D.Beneficial ownership—9.6%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
BCLS Fund III Investments, LPBeneficial ownership—6.8%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
BCLS Fund III Investments, LPBeneficial ownership—4.8%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
Chen Yu, M.D., M.B.A.Beneficial ownership—4.8%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Chen Yu, M.D., M.B.A.Beneficial ownership—3.4%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
Simeon George, M.D., M.B.A.Beneficial ownership—11.1%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Simeon George, M.D., M.B.A.Beneficial ownership—7.8%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
Erez Chimovits, M.B.A.Beneficial ownership—12.2%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Erez Chimovits, M.B.A.Beneficial ownership—8.6%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
Carl L. Gordon, Ph.D., CFABeneficial ownership—30.8%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Carl L. Gordon, Ph.D., CFABeneficial ownership—21.8%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
All current executive officers and directors as a group (14 persons)Beneficial ownership—50.2%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
All current executive officers and directors as a group (14 persons)Beneficial ownership—36.1%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
Executive officers, directors, pre-offering >5%stockholders and their respective affiliatesOwnership as disclosed—approximately 54%Beneficial—
Literal complete collective group; Upon closing of offering and concurrent private placement; Approximately54%; August25,2026share basis; no group purchases in offering or concurrent private placement. Percentage applies to the source complete group, not any individual or truncated subgroup; full original conditions retained.DisclosedEvidence
common stockper-share voting rights——1 vote per shareVotes per share
Literal source per-share voting entitlement; common stock; non-cumulative voting; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retainedDisclosedEvidence
Source and calculation ↗
our executive officers, directors and stockholders who · our executive officers, directors and stockholders who — Ownership as disclosed · >5%

Source statement; >; source predicate: owned; primary source clause; source condition: assuming no purchase of shares in this offering and concurrent private placement by any of this group); source scope: of our outstanding common stock before this offering and concurrent private placement and their respective affiliates will, in the aggregate, hold approximately; not an additive ownership partition

Upon the closing of this offering and concurrent private placement, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and concurrent private placement and their respective affiliates will, in the aggregate, hold approximately 54% of our outstanding common stock (based on the number of shares of our outstanding common stock as of August 25, 2026 and assuming no purchase of shares in this offering and concurrent private placement by any of this group). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily of those of other stockholders, including seeking a premium value for their shares of our common stock. Any of these actions could adversely affect the market price of our common stock.

0001193125-26-403094 · SEC ownership paragraph; source 591950:593489; SHA256 2aabb3a3b8e45fe6b39e0e9e37055405e54cd66b675b1dca4b7b43b108b63fd7 ↗

our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and concurrent private placement and their respective affiliates · our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and concurrent private placement and their respective affiliates — Ownership as disclosed · approximately 54%

Source statement; approximately ; source predicate: will, in the aggregate, hold; primary source clause; source condition: assuming no purchase of shares in this offering and concurrent private placement by any of this group); source scope: of our outstanding common stock (based on the number of shares of our outstanding common stock as of August 25, 2026 and assuming no purchase of shares in this offering and concurrent private placeme; not an additive ownership partition

Upon the closing of this offering and concurrent private placement, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and concurrent private placement and their respective affiliates will, in the aggregate, hold approximately 54% of our outstanding common stock (based on the number of shares of our outstanding common stock as of August 25, 2026 and assuming no purchase of shares in this offering and concurrent private placement by any of this group). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily of those of other stockholders, including seeking a premium value for their shares of our common stock. Any of these actions could adversely affect the market price of our common stock.

0001193125-26-403094 · SEC ownership paragraph; source 591950:593489; SHA256 2aabb3a3b8e45fe6b39e0e9e37055405e54cd66b675b1dca4b7b43b108b63fd7 ↗

Entities affiliated with OrbiMed · Entities affiliated with OrbiMed — Beneficial shares · 23,255,789

Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition

Raw source column: Number ofshares ofbeneficiallyowned; source holder: Entities affiliated with OrbiMed(1)

0001193125-26-403094 · SEC table 559 row 6 columns 4; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:3 ↗

Entities affiliated with LAV Fund · Entities affiliated with LAV Fund — Beneficial shares · 11,858,655

Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition

Raw source column: Number ofshares ofbeneficiallyowned; source holder: Entities affiliated with LAV Fund(2)

0001193125-26-403094 · SEC table 559 row 7 columns 4; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:3 ↗

Entities affiliated with SR One · Entities affiliated with SR One — Beneficial shares · 8,336,661

Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition

Raw source column: Number ofshares ofbeneficiallyowned; source holder: Entities affiliated with SR One(3)

0001193125-26-403094 · SEC table 559 row 8 columns 4; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:3 ↗

Zhen Li, Ph.D. · Zhen Li, Ph.D. — Beneficial shares · 10,748,214

Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition

Raw source column: Number ofshares ofbeneficiallyowned; source holder: Zhen Li, Ph.D.(4)

0001193125-26-403094 · SEC table 559 row 9 columns 4; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:3 ↗

BCLS Fund III Investments, LP · BCLS Fund III Investments, LP — Beneficial shares · 5,128,970

Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition

Raw source column: Number ofshares ofbeneficiallyowned; source holder: BCLS Fund III Investments, LP(5)

0001193125-26-403094 · SEC table 559 row 10 columns 4; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:3 ↗

A. Robert MacLeod, Ph.D. · A. Robert MacLeod, Ph.D. — Beneficial shares · 491,898

Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition

Raw source column: Number ofshares ofbeneficiallyowned; source holder: A. Robert MacLeod, Ph.D.(7)

0001193125-26-403094 · SEC table 560 row 9 columns 4; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:3 ↗

Chen Yu, M.D., M.B.A. · Chen Yu, M.D., M.B.A. — Beneficial shares · 3,590,279

Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition

Raw source column: Number ofshares ofbeneficiallyowned; source holder: Chen Yu, M.D., M.B.A.(8)

0001193125-26-403094 · SEC table 560 row 11 columns 4; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:3 ↗

Simeon George, M.D., M.B.A. · Simeon George, M.D., M.B.A. — Beneficial shares · 8,336,661

Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition

Raw source column: Number ofshares ofbeneficiallyowned; source holder: Simeon George, M.D., M.B.A.(3)

0001193125-26-403094 · SEC table 560 row 12 columns 4; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:3 ↗

Erez Chimovits, M.B.A. · Erez Chimovits, M.B.A. — Beneficial shares · 9,230,509

Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition

Raw source column: Number ofshares ofbeneficiallyowned; source holder: Erez Chimovits, M.B.A.(1)

0001193125-26-403094 · SEC table 560 row 13 columns 4; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:3 ↗

Carl L. Gordon, Ph.D., CFA · Carl L. Gordon, Ph.D., CFA — Beneficial shares · 23,255,789

Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition

Raw source column: Number ofshares ofbeneficiallyowned; source holder: Carl L. Gordon, Ph.D., CFA(1)

0001193125-26-403094 · SEC table 560 row 14 columns 4; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:3 ↗

All current executive officers and directors as a group (14 persons) · All current executive officers and directors as a group (14 persons) — Beneficial shares · 50,193,162

Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition

Raw source column: Number ofshares ofbeneficiallyowned; source holder: All current executive officers and directors as a group (14 persons)(10)

0001193125-26-403094 · SEC table 560 row 19 columns 4; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:3 ↗

Entities affiliated with OrbiMed · Entities affiliated with OrbiMed — Beneficial ownership · 30.8%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with OrbiMed(1)

0001193125-26-403094 · SEC table 559 row 6 columns 8; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:6,4:2 ↗

Entities affiliated with OrbiMed · Entities affiliated with OrbiMed — Beneficial ownership · 21.8%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with OrbiMed(1)

0001193125-26-403094 · SEC table 559 row 6 columns 12; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:6,4:5 ↗

Entities affiliated with LAV Fund · Entities affiliated with LAV Fund — Beneficial ownership · 15.7%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with LAV Fund(2)

0001193125-26-403094 · SEC table 559 row 7 columns 8; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:6,4:2 ↗

Entities affiliated with LAV Fund · Entities affiliated with LAV Fund — Beneficial ownership · 11.1%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with LAV Fund(2)

0001193125-26-403094 · SEC table 559 row 7 columns 12; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:6,4:5 ↗

Entities affiliated with SR One · Entities affiliated with SR One — Beneficial ownership · 11.1%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with SR One(3)

0001193125-26-403094 · SEC table 559 row 8 columns 8; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:6,4:2 ↗

Entities affiliated with SR One · Entities affiliated with SR One — Beneficial ownership · 7.8%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with SR One(3)

0001193125-26-403094 · SEC table 559 row 8 columns 12; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:6,4:5 ↗

Zhen Li, Ph.D. · Zhen Li, Ph.D. — Beneficial ownership · 13.4%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Zhen Li, Ph.D.(4)

0001193125-26-403094 · SEC table 559 row 9 columns 8; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:6,4:2 ↗

Zhen Li, Ph.D. · Zhen Li, Ph.D. — Beneficial ownership · 9.6%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Zhen Li, Ph.D.(4)

0001193125-26-403094 · SEC table 559 row 9 columns 12; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:6,4:5 ↗

BCLS Fund III Investments, LP · BCLS Fund III Investments, LP — Beneficial ownership · 6.8%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: BCLS Fund III Investments, LP(5)

0001193125-26-403094 · SEC table 559 row 10 columns 8; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:6,4:2 ↗

BCLS Fund III Investments, LP · BCLS Fund III Investments, LP — Beneficial ownership · 4.8%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: BCLS Fund III Investments, LP(5)

0001193125-26-403094 · SEC table 559 row 10 columns 12; source 1532025:1538830; SHA256 25268a886c7ab86f56e3d14ca2f2153d2d65d7d9f7fd8824dcffa63f3994be32; ownership header cells 3:6,4:5 ↗

Chen Yu, M.D., M.B.A. · Chen Yu, M.D., M.B.A. — Beneficial ownership · 4.8%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Chen Yu, M.D., M.B.A.(8)

0001193125-26-403094 · SEC table 560 row 11 columns 8; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:6,4:2 ↗

Chen Yu, M.D., M.B.A. · Chen Yu, M.D., M.B.A. — Beneficial ownership · 3.4%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Chen Yu, M.D., M.B.A.(8)

0001193125-26-403094 · SEC table 560 row 11 columns 12; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:6,4:5 ↗

Simeon George, M.D., M.B.A. · Simeon George, M.D., M.B.A. — Beneficial ownership · 11.1%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Simeon George, M.D., M.B.A.(3)

0001193125-26-403094 · SEC table 560 row 12 columns 8; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:6,4:2 ↗

Simeon George, M.D., M.B.A. · Simeon George, M.D., M.B.A. — Beneficial ownership · 7.8%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Simeon George, M.D., M.B.A.(3)

0001193125-26-403094 · SEC table 560 row 12 columns 12; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:6,4:5 ↗

Erez Chimovits, M.B.A. · Erez Chimovits, M.B.A. — Beneficial ownership · 12.2%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Erez Chimovits, M.B.A.(1)

0001193125-26-403094 · SEC table 560 row 13 columns 8; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:6,4:2 ↗

Erez Chimovits, M.B.A. · Erez Chimovits, M.B.A. — Beneficial ownership · 8.6%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Erez Chimovits, M.B.A.(1)

0001193125-26-403094 · SEC table 560 row 13 columns 12; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:6,4:5 ↗

Carl L. Gordon, Ph.D., CFA · Carl L. Gordon, Ph.D., CFA — Beneficial ownership · 30.8%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Carl L. Gordon, Ph.D., CFA(1)

0001193125-26-403094 · SEC table 560 row 14 columns 8; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:6,4:2 ↗

Carl L. Gordon, Ph.D., CFA · Carl L. Gordon, Ph.D., CFA — Beneficial ownership · 21.8%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Carl L. Gordon, Ph.D., CFA(1)

0001193125-26-403094 · SEC table 560 row 14 columns 12; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:6,4:5 ↗

All current executive officers and directors as a group (14 persons) · All current executive officers and directors as a group (14 persons) — Beneficial ownership · 50.2%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: All current executive officers and directors as a group (14 persons)(10)

0001193125-26-403094 · SEC table 560 row 19 columns 8; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:6,4:2 ↗

All current executive officers and directors as a group (14 persons) · All current executive officers and directors as a group (14 persons) — Beneficial ownership · 36.1%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: All current executive officers and directors as a group (14 persons)(10)

0001193125-26-403094 · SEC table 560 row 19 columns 12; source 1539316:1552845; SHA256 847e67070b6922830deac792a411e53f3bd913881b1d9227489c3e29e9c6936a; ownership header cells 3:6,4:5 ↗

Executive officers, directors, pre-offering >5%stockholders and their respective affiliates · Executive officers, directors, pre-offering >5%stockholders and their respective affiliates — Ownership as disclosed · approximately 54%

Literal complete collective group; Upon closing of offering and concurrent private placement; Approximately54%; August25,2026share basis; no group purchases in offering or concurrent private placement. Percentage applies to the source complete group, not any individual or truncated subgroup; full original conditions retained.

Upon the closing of this offering and concurrent private placement, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and concurrent private placement and their respective affiliates will, in the aggregate, hold approximately 54% of our outstanding common stock (based on the number of shares of our outstanding common stock as of August 25, 2026 and assuming no purchase of shares in this offering and concurrent private placement by any of this group). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily of those of other stockholders, including seeking a premium value for their shares of our common stock. Any of these actions could adversely affect the market price of our common stock.

0001193125-26-403094 · SEC ownership paragraph; source 591950:593489; SHA256 2aabb3a3b8e45fe6b39e0e9e37055405e54cd66b675b1dca4b7b43b108b63fd7 ↗

common stock · common stock — per-share voting rights · 1 vote per share

Literal source per-share voting entitlement; common stock; non-cumulative voting; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained

Our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election. Source context: Upon the filing of our amended and restated certificate of incorporation and the closing of this offering, our authorized capital stock will consist of 999,999,999 shares of our common stock, par value $0.0001 per share, and 10,000,000 shares of our preferred stock, par value $0.0001 per share. All of our authorized preferred stock upon the closing of this offering will be undesignated. The following is a summary of the rights of our common and preferred stockholders and some of the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the closing of this offering, respectively, and of the Delaware General Corporation Law. This summary is not complete. For more detailed information, please see our amended and restated certificate of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the Delaware General Corporation Law.

0001193125-26-403094 · SEC ownership excerpt; source 1573010:1573475; SHA256 ac08e358ee4fad9a882777cc124d54fa974bafc026cc116e707c05f3be386aad; context source 1570267:1571416; SHA256 3d09e8fb9bff5743a035ba89124dc04843b6c318d4eddc002d6a05341fd1b6b7 ↗

Economic ownership

A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.

Share supply

Source lock-up conditions

Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph

Source lock-up conditions
MeasureReported value
WeAfter date of this prospectus · Source conditions apply180 days
We and our officers, directors, and holders of substantially all of our common stockAfter date of this prospectus · Source conditions apply180 days
Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties)After date of this prospectus · Source conditions apply180 days
Source and calculation
We

We have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of our common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of our common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC for a period of 180 days after the date of this prospectus, other than the shares of our common stock to be sold in this offering.

SEC lock-up paragraph; source 1666316:1667551; SHA256 fee022aa99bd0286e9ac52b1047a46d5eb69d09b2887e725528fce2da1c4a676 ↗
We and our officers, directors, and holders of substantially all of our common stock

We and our officers, directors, and holders of substantially all of our common stock have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of our common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC. This agreement does not apply to any existing employee benefit plans. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC have advised us that they have no current intent or arrangement to release any of the shares subject to the lock-up agreements prior to the expiration of the lock-up agreements. Shares to be purchased by AbbVie in the concurrent private placement will not be subject to a lock-up agreement but will be restricted shares under Rule 144 with a holding period to begin on the closing date of the concurrent private placement.

SEC lock-up paragraph; source 1619991:1621225; SHA256 562044a6ca982f4a5c431ffd1be16c5f3bc5524182ba56a8b44e3240d75e6a85 ↗
Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties)

Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties) have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the restricted period), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock (including, without limitation, shares of our common stock or such other securities

SEC lock-up paragraph; source 1669579:1670795; SHA256 12de0fb4c05b8294fb44424dd0053cfb4535ddca502bc0a98097a9b7f6d7532c ↗

Conditional lock-up timeline

Conditional lock-up timeline

Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.

date of this prospectus

  1. WeWe have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of our common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of our common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC for a period of 180 days after the date of this prospectus, other than the shares of our common stock to be sold in this offering.
  2. We and our officers, directors, and holders of substantially all of our common stockWe and our officers, directors, and holders of substantially all of our common stock have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of our common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC. This agreement does not apply to any existing employee benefit plans. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC have advised us that they have no current intent or arrangement to release any of the shares subject to the lock-up agreements prior to the expiration of the lock-up agreements. Shares to be purchased by AbbVie in the concurrent private placement will not be subject to a lock-up agreement but will be restricted shares under Rule 144 with a holding period to begin on the closing date of the concurrent private placement.
  3. Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties)Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties) have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the restricted period), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock (including, without limitation, shares of our common stock or such other securities
Holder / event
Holder / eventTerm / dateConditions
We180 daysWe have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of our common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of our common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC for a period of 180 days after the date of this prospectus, other than the shares of our common stock to be sold in this offering.
We and our officers, directors, and holders of substantially all of our common stock180 daysWe and our officers, directors, and holders of substantially all of our common stock have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of our common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC. This agreement does not apply to any existing employee benefit plans. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC have advised us that they have no current intent or arrangement to release any of the shares subject to the lock-up agreements prior to the expiration of the lock-up agreements. Shares to be purchased by AbbVie in the concurrent private placement will not be subject to a lock-up agreement but will be restricted shares under Rule 144 with a holding period to begin on the closing date of the concurrent private placement.
Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties)180 daysOur directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties) have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the restricted period), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock (including, without limitation, shares of our common stock or such other securities
Basis and evidence
We

We have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of our common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of our common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC for a period of 180 days after the date of this prospectus, other than the shares of our common stock to be sold in this offering.

SEC lock-up paragraph; source 1666316:1667551; SHA256 fee022aa99bd0286e9ac52b1047a46d5eb69d09b2887e725528fce2da1c4a676 ↗
We and our officers, directors, and holders of substantially all of our common stock

We and our officers, directors, and holders of substantially all of our common stock have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of our common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC. This agreement does not apply to any existing employee benefit plans. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC have advised us that they have no current intent or arrangement to release any of the shares subject to the lock-up agreements prior to the expiration of the lock-up agreements. Shares to be purchased by AbbVie in the concurrent private placement will not be subject to a lock-up agreement but will be restricted shares under Rule 144 with a holding period to begin on the closing date of the concurrent private placement.

SEC lock-up paragraph; source 1619991:1621225; SHA256 562044a6ca982f4a5c431ffd1be16c5f3bc5524182ba56a8b44e3240d75e6a85 ↗
Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties)

Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties) have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the restricted period), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock (including, without limitation, shares of our common stock or such other securities

SEC lock-up paragraph; source 1669579:1670795; SHA256 12de0fb4c05b8294fb44424dd0053cfb4535ddca502bc0a98097a9b7f6d7532c ↗

Financial quality

Bars compare absolute amounts within each measure. Each measure has its own scale.

Net income / (loss)

$ · Annual values as reported · Consolidated
FY2024($46,360)
FY2025($73,088)

Operating cash flow

$ · Annual values as reported · Consolidated
FY2024($48,563)
FY2025$262,288
Financial quality
CalculationFY2024FY2025
Net income / (loss)Consolidated($46,360)($73,088)
Operating cash flowConsolidated($48,563)$262,288
Financial quality
CalculationReported value
Cash and cash equivalents2025-12-31 · Consolidated$66,517
Cash and cash equivalents2024-12-31 · Consolidated$14,034
Current assets2025-12-31 · Consolidated$493,375
Current assets2024-12-31 · Consolidated$225,667
Total assets2025-12-31 · Consolidated$507,655
Total assets2024-12-31 · Consolidated$233,454
Current liabilities2025-12-31 · Consolidated$30,485
Current liabilities2024-12-31 · Consolidated$8,937
Total liabilities2025-12-31 · Consolidated$352,288
Total liabilities2024-12-31 · Consolidated$12,977
Total equity / (deficit)2025-12-31 · Consolidated($202,255)
Total equity / (deficit)2024-12-31 · Consolidated($137,145)
General and administrative expensesFY2025 · Consolidated$20,302
General and administrative expensesFY2024 · Consolidated$14,876
Cash and cash equivalents2026-06-30 · Consolidated · Unaudited$58,484
Current assets2026-06-30 · Consolidated · Unaudited$441,543
Total assets2026-06-30 · Consolidated · Unaudited$456,332
Current liabilities2026-06-30 · Consolidated · Unaudited$34,013
Total liabilities2026-06-30 · Consolidated · Unaudited$349,762
Total equity / (deficit)2026-06-30 · Consolidated · Unaudited($251,052)
General and administrative expenses6M ended 2026-06-30 · Consolidated$11,514
General and administrative expenses6M ended 2025-06-30 · Consolidated$9,253
Net income / (loss)6M ended 2026-06-30 · Consolidated($48,426)
Net income / (loss)6M ended 2025-06-30 · Consolidated($33,644)
Basis and evidence
Cash and cash equivalents
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Cash and cash equivalents
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current assets
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total assets
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current liabilities
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total liabilities
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total stockholders’ deficit
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
General and administrative
FY2025; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
General and administrative
FY2024; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net loss
FY2025; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net loss
FY2024; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net cash provided by (used in) operating activities
FY2025; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net cash provided by (used in) operating activities
FY2024; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Cash and cash equivalents
June 30, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total current assets
June 30, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total assets
June 30, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total current liabilities
June 30, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total liabilities
June 30, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total stockholders’ deficit
June 30, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
General and administrative
6M ended 2026-06-30; consolidated; currency symbol as printed ($); ISO currency not assigned; 6 months ended 2026-06-30
General and administrative
6M ended 2025-06-30; consolidated; currency symbol as printed ($); ISO currency not assigned; 6 months ended 2025-06-30
Net loss
6M ended 2026-06-30; consolidated; currency symbol as printed ($); ISO currency not assigned; 6 months ended 2026-06-30
Net loss
6M ended 2025-06-30; consolidated; currency symbol as printed ($); ISO currency not assigned; 6 months ended 2025-06-30
Financial quality and runway
Financial review

Financial quality and runway

Latest supplied financial period is the six months ended June 30, 2026, with audited full-year data for 2024 and 2025. Six-month 2026 revenue was $2.886 million and net loss was $48.426 million; June 30, 2026 cash, cash equivalents and short-term investments were $427.252 million. Debt and going-concern conclusions are not supplied.

Cash and cash equivalents$66,517
Cash and cash equivalents$14,034
Total current assets$493,375
EvidenceFinancial review 1

Six-month 2026 collaboration revenue was $2.886 million; operating loss was $56.947 million.

EvidenceFinancial review 2

Net loss increased from $46.360 million in 2024 to $73.088 million in 2025.

EvidenceFinancial review 3

The company relies on scaled EGC and smaller-reporting-company disclosure, including only two audited fiscal years.

Source · Implications of being an emerging growth company and a smaller reporting companyOpen 424B4 ↗
LATEST COMPARISON

MATERIAL CHANGES

The latest material signals and their investor impact are shown below.

Open 424B4 ↗
CHANGE 01Offer size

Why it mattersThe marketed IPO increased from 21.875 million to 26.25 million shares, increasing primary issuance and proceeds.

Evidence · The offering
CHANGE 02Price

Why it mattersThe preliminary $15.00–$17.00 range became a $17.00 fixed IPO price.

Evidence · Cover and opening disclosure
CHANGE 03Listing status

Why it mattersThe current filing says listing approval was obtained, replacing the prior application and contingency language.

Evidence · Cover and opening disclosure
IPO177 explains the investment effect; the SEC source remains the authoritative record. Page-level locators are shown only when extracted and verified.

Loading filing history…

Risk 1

The company has not completed any clinical programs and has no products approved for commercial sale.

Risk 2

The company expects significant losses and may require substantial additional funding, causing future dilution.

Risk 3

Third parties conduct preclinical studies, clinical trials and manufacturing, creating execution and timing dependencies.

Risk 4

Existing officers, directors and principal stockholders may control or significantly influence stockholder matters if acting together.

Document424B40001193125-26-403094
Filed2026-09-28SEC EDGAR
Research updated2026-09-28Analysed
Source-bound table inputs74SEC EDGAR
Open filing ↗